NASDAQ$UTMD
Utah Medical Products Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Achieved financial results consistent with beginning of year projections.
Utah Medical Products reported a decrease in revenue and operating income for the second quarter of 2023, but net income and earnings per share increased. The company's balance sheet remained strong with increased cash and investments.
- Worldwide sales decreased by 4.2% compared to Q2 2022.
- Sales outside the U.S. outperformed domestic sales, with OUS sales increasing by 4.5% and U.S. domestic sales decreasing by 10.4%.
- Operating income decreased by 12.5% due to lower gross profit and higher litigation and salary expenses.
- Net income increased by 2.3% due to a lower estimated income tax provision rate and fewer diluted shares.
Headline financials
Revenue & EPS history
Utah Medical · Revenue · Quarterly
$12.9M
Revenue by segment
Utah Medical · $7.98M total across 3 segments · Q1 2022
- Direct Sales$3.99M—50.0%
- OEM Sales$2.72M+42.6%34.0%
- Filshie Device Sales$1.28M—16.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+0.7%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+6.8%
Q2 2019
Best reaction
-11.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -4.3% | -7.5% | |
| Q4 2025 | +1.2% | +1.9% | +9.5% | |
| Q3 2025 | -1.1% | -1.9% | -6.0% | |
| Q1 2025 | -0.2% | +0.9% | +4.3% | |
| Q4 2024 | -1.8% | -4.6% | -6.9% | |
| Q3 2024 | -0.3% | -0.2% | +1.4% | |
| Q2 2024 | -7.4% | -7.2% | -8.6% | |
| Q1 2024 | -1.8% | -1.4% | -0.2% | |
| Q4 2023 | -4.3% | -7.0% | -15.2% | |
| Q3 2023 | -3.1% | +0.0% | +4.2% | |
| Q2 2023 | +0.0% | +0.5% | -2.8% | |
| Q1 2023 | +0.8% | +0.8% | -0.6% | |
| Q4 2022 | +3.9% | +5.5% | +4.7% | |
| Q3 2022 | +3.5% | -1.3% | -0.1% | |
| Q2 2022 | +3.6% | +6.3% | +6.7% | |
| Q1 2022 | -1.2% | -3.1% | -4.6% | |
| Q4 2021 | -3.4% | -0.3% | -5.9% | |
| Q3 2021 | +4.7% | +1.7% | +30.7% | |
| Q2 2021 | +0.2% | +2.9% | -0.2% | |
| Q1 2021 | +0.6% | +0.8% | -0.4% | |
| Q4 2020 | +3.5% | +5.7% | +0.8% | |
| Q3 2020 | -3.4% | -1.7% | +6.3% | |
| Q2 2020 | -5.3% | -7.6% | -6.7% | |
| Q1 2020 | -1.8% | +4.5% | +11.7% | |
| Q4 2019 | -11.7% | -13.9% | -16.2% | |
| Q3 2019 | +1.1% | +7.1% | +9.2% | |
| Q2 2019 | +6.8% | +9.3% | +15.6% | |
| Q1 2019 | -0.8% | -1.5% | -5.2% | |
| Q4 2018 | +3.4% | +5.1% | -5.2% | |
| Q3 2018 | +0.7% | +1.7% | +8.8% | |
| Q2 2018 | -1.7% | +2.1% | -5.8% | |
| Q1 2018 | -2.2% | -2.7% | -2.7% | |
| Q4 2017 | -0.2% | +0.2% | -3.0% | |
| Q3 2017 | +0.3% | +1.1% | +6.6% | |
| Q2 2017 | -0.4% | -2.7% | -1.1% | |
| Q1 2017 | +0.4% | -0.2% | +3.7% | |
| Q4 2016 | -1.2% | +1.0% | +1.1% | |
| Q3 2016 | +0.8% | +1.1% | +10.4% | |
| Q2 2016 | -1.3% | -2.0% | -2.6% | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | +0.9% | — | — | |
| Q3 2015 | +4.6% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | +2.1% | — | — | |
| Q4 2014 | -4.7% | — | — | |
| Q3 2014 | -0.0% | — | — | |
| Q2 2014 | +2.8% | — | — | |
| Q1 2014 | -6.5% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | -0.7% | — | — | |
| Q2 2013 | +0.7% | — | — | |
| Q1 2013 | +3.6% | — | — | |
| Q4 2012 | +6.8% | — | — | |
| Q4 2011 | +6.8% | — | — | |
| Q3 2012 | +1.9% | — | — | |
| Q2 2012 | -0.1% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q1 2012 | -0.7% | — | — | |
| Q4 2009 | -0.8% | — | — | |
| Q3 2010 | -2.3% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q1 2010 | +4.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro